The imposition of import tariffs and their effects on global trade are threatening to upend essential cross-border supply chains that the biomedical industries are built on. Plenary Session 1 gathers biotech leaders from Asia and around the world to discuss this and other topics important to the industry, including Taiwan's role in today's biotech industry; the current state of international collaborations; and the biotech industry's strategic importance, both now and in the future. The highlight of the session will be the Tang Prize Lecture featuring Jens Juul Holst and spotlighting his groundbreaking work on GLP-1, a discovery transforming diabetes treatment and metabolic health worldwide. 

Continuing with the themes of Session 1, Plenary Session 2 highlights transformative biotech strategies shaping the Asia-Pacific region and beyond. Discussions will cover how to advance regional innovation and patient access; how genomics is redefining the future of healthcare and life sciences investment, as well as other highly-pertinent topics. The session promises dialogue at the intersection of science, policy, and business, providing a forward-facing perspective on biotech’s evolving impact and global potential.

Plenary Session 3 is Taiwan-focused, and will explore how innovation drives public health and sustainable growth on the island. The session will emphasize Taiwan’s strategic role in the life sciences ecosystem, highlighting policy frameworks fostering innovation and accessibility. Thought leaders from the pharmaceutical, biotech, and healthcare sectors will examine the current state of local R&D, current levels of digital transformation in Taiwan, and recent cross-sector collaboration. Discussion will also delve into aligning innovation with healthcare equity and long-term societal value. This session reinforces the critical link between scientific advancement and a healthier, more resilient Taiwan.